Individual patient demographic and body measurement data recorded at Screening will be listed , consent date will also be presented . 4.5.2 Medical History of Pancreatic Cancer and KRAS Mutation Analysis The number and percentage of patients with KRAS mutation detected (yes/no) and by mutation type (codon12/13, codon 61, other) will be presented. Percentages will respectively be based on the number of patients with tumour sample retained for KRAS status determination and the number of patients with KRAS mutation detected. Descriptive summary statistics will be presented for t ime from diagnosis to first IMP administration ( weeks ), time from diagnosis to surgery (weeks) and time from su rgery to first IMP administration ( weeks ). The number and percentage of patients by disease staging at diagnosis and resection surgery outcome will be also be displayed. Time from diagnosis to first IMP administration (weeks) is calculated as (date of fir st IMP administration – date of diagnosis + 1) / 7 rounded to 1 decimal place. Time from diagnosis to surgery (weeks) is calculated as (date of surgery – date of diagnosis + 1) / 7 rounded to 1 decimal place . Time from surgery to first IMP administration (weeks) is calculated as (date of first IMP administration – date of surgery + 1) / 7 rounded to 1 decimal place. All pancreatic cancer medical history details will be listed along with KRAS status if a tumo ur sample was taken for KRAS status determination.